Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

The phosphatidylinositol‐3 kinase (PI3K)–AKT pathway is one of the most commonly
dysregulated pathways in all of cancer, with somatic mutations, copy number alterations …

Luminal cells are believed to be the cells of origin for human prostate cancer, because the
disease is characterized by luminal cell expansion and the absence of basal cells. Yet …

Benign prostatic hyperplasia (BPH) is a benign enlargement of the prostate in which
incidence increases linearly with age, beginning at about 50 years old. BPH is a significant …

Animal models, particularly mouse models, play a central role in the study of the etiology,
prevention, and treatment of human prostate cancer. While tissue culture models are …

The Polycomb group transcriptional repressor Bmi-1 is often upregulated in prostate cancer,
but its functional roles in prostate stem cell maintenance and prostate cancer are unclear …